BioNTech says no need to waive patents On Vaccine


German pharmaceutical company BioNTech said that it was not necessary to give up patents on coronavirus vaccines because manufacturers will be able to produce enough vaccines to supply the world over the coming year. On a call with investors reporting the company’s first quarter net profit of $ 1.37 billion, Sahin said BioNTech and its US partner Pfizer have already delivered vaccines to more than 90 countries and more than doubled its expected production capacity for the year.

“We have now increased manufacturing capacity to 3 billion doses in 2021, and over 40 percent of those doses are expected to go to middle- and low-income countries,” Sahin said. Waiving patents would not alleviate supply shortages in the coming months, he said, citing the complexity of producing the mRNA-based vaccine his company developed last year.